Emergent BioSolutions filings document an operating public-health company with NYSE-listed common stock under the symbol EBS. Its Form 8-K reports cover financial results, investor presentations, Regulation FD materials, debt prepayments, credit agreements, and other capital-structure events tied to its term loan and asset-based revolving facility.
Proxy and annual-meeting filings describe board elections, director appointments, committee service, auditor ratification, executive compensation, equity awards, and stockholder voting results. The filing record also captures governance disclosures for a company supplying NARCAN® Nasal Spray, ACAM2000®, and other medical countermeasure and bioservices products.
Emergent BioSolutions director reported multiple stock transactions in the company’s shares. On December 5, 2025, the director exercised 25,748 stock options at an exercise price of $5.02 per share, receiving the same number of common shares. To cover the option exercise price and applicable taxes, 10,864 shares were sold, with additional open‑market sales of 7,100 shares at a weighted average price of $12.1113 and 14,884 shares at a weighted average price of $11.8978. After these transactions, the director held 98,417 shares of common stock directly and no remaining derivative securities from this option grant.
EBS reported a planned insider sale under Rule 144. A company affiliate intends to sell 32,848 shares of common stock, with an aggregate market value of $392,334.78, through Morgan Stanley Smith Barney LLC on the NYSE around 12/05/2025. The issuer has 52,519,964 shares outstanding, providing context for the size of this transaction.
The shares come from a mix of restricted stock awards granted between 2021 and 2022 and a stock option exercise for 25,748 shares paid in cash on 12/05/2025. By signing the notice, the seller represents that they are not aware of any material adverse information about EBS’s current or prospective operations that has not been publicly disclosed.
Emergent BioSolutions (EBS) reported an insider transaction on a Form 4 for its SVP, Bioservices. On 11/11/2025, 610 shares of common stock were withheld under transaction code F, which represents shares withheld to cover taxes upon the vesting and settlement of restricted stock units. The shares were valued at $10.88 for withholding purposes. Following this administrative transaction, the officer directly beneficially owns 103,082 shares of EBS common stock.
Emergent BioSolutions (EBS) — Form 4 insider transaction. A director reported selling 17,801 shares of common stock on 11/10/2025 at a weighted average price of $10.54, with trade prices ranging from $10.33 to $10.79. The sale was executed under a Rule 10b5-1 trading plan dated August 11, 2025, established to cover tax obligations from RSUs that vested on October 2, 2025. Following the transaction, the reporting person beneficially owns 119,858 shares.
Emergent BioSolutions announced the planned retirement of director Louis W. Sullivan, M.D., effective November 14, 2025. The company stated his decision is not due to any disagreement regarding operations, policies, or practices.
Dr. Sullivan has served on the board since June 2006, most recently as Chairman of the Compensation Committee and a member of the Nominating and Corporate Governance Committee. The company issued a press release on November 12, 2025, furnished as Exhibit 99.1.
Emergent BioSolutions (EBS): Director sale reported. A director sold 8,552 shares of common stock on 11/07/2025 at $10.00 per share in an open-market transaction coded “S.” The trade was executed under a Rule 10b5-1(c) trading plan adopted on August 8, 2025. Following the sale, the director beneficially owns 88,980 shares held directly.
Emergent BioSolutions (EBS) received a Form 144 notice for a proposed sale of 17,801 common shares, showing an aggregate market value of $187,544.22. The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services as broker and identifies the NYSE as the exchange, with an approximate sale date of 11/10/2025.
The shares were acquired as restricted stock from the issuer on 10/02/2025, in the same amount of 17,801 shares. The notice also reports a prior sale in the last three months by Donald DeGolyer of 7,844 common shares on 08/12/2025 for $67,830.99. Shares outstanding are listed as 52,519,964.
Emergent BioSolutions (EBS): Form 144 notice to sell shares. An affiliate filed to sell 8,552 shares of common stock through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of $85,520, with an approximate sale date of 11/07/2025 on the NYSE.
The shares reflect restricted stock awards acquired on 05/08/2025 (6,972 shares) and 07/20/2025 (1,580 shares). The company reports 52,519,964 shares outstanding. This notice states the seller does not know any material adverse information that has not been publicly disclosed.
Emergent BioSolutions (EBS) reported third‑quarter 2025 results. Total revenue was $231.1 million versus $293.8 million a year ago, while net income was $51.2 million versus $114.8 million. Year‑to‑date, revenue totaled $594.2 million versus $848.9 million, and net income reached $107.2 million compared to a loss of $(159.3) million in 2024, reflecting lower operating expenses and non‑operating gains.
Cash and cash equivalents rose to $245.5 million from $99.5 million at year‑end, supported by $92.9 million in operating cash flow. Inventories were $356.3 million. Gross debt stood at $693.1 million (including $443.1 million of 3.875% Senior Notes due 2028 and a $250.0 million term loan due 2029); net carrying value after issuance costs was $663.1 million. The company repurchased $15.8 million of common stock year‑to‑date.
Strategic actions continued: Emergent recognized $50.0 million in 2025 milestone receipts from the prior Travel Health sale and recorded a $12.2 million loss on assets held for sale related to Maryland warehouse space. As of October 22, 2025, there were 52,519,964 common shares outstanding.
Emergent BioSolutions (EBS) furnished its quarterly results update. The company announced financial and operating results for the quarter ended September 30, 2025 via a press release, and scheduled a conference call on October 29, 2025 to discuss the quarter. The press release is furnished as Exhibit 99.1 and the earnings call presentation as Exhibit 99.2.
The materials in Items 2.02 and 7.01 and Exhibits 99.1 and 99.2 are furnished, not filed, under the Exchange Act. The company noted the call slides would be posted on its website.